Clinical Trials Logo

Clinical Trial Summary

Cancer is a complex disease; its different causes and types have a strong impact on patient treatment and prognosis. To improve understanding of the disease, its causes and progression, the investigators will develop a simple, cost-effective system for continuous control of mucosal lesions with non-invasive brush biopsy that can be managed in primary dental care, as an alternative to tissue biopsy in order to reduce the number of oral cavity cancers.


Clinical Trial Description

In Sweden, about 1,200 cases of cancer of the oral cavity, lips and throat are diagnosed each year. This is significantly higher than the global age-standardized incidence of 6.1 per 100,000 inhabitants, including all ages and genders. Oral cancer is a serious and growing public health problem and leads to significantly reduced quality of life after extensive treatment that usually includes radiation therapy and surgery. Patients often have pain, swallowing problems, dry mouth that causes tooth status, negatively affected appearance, family life and social interaction. Although it is well known that early diagnostic screening is of great importance for increasing survival, there is a lack of a nationally organized screening program of high-risk individuals, tobacco users and individuals with overconsumption of alcohol. As a result, many cases are diagnosed late and therefore have poor prognosis. The five-year survival rate in Sweden for the diagnosis of oral cancer is about 60%. If the tumor is small when diagnosed, without lymph node involvement or metastases,and treated correctly, a survival rate of 90% can be achieved while in a late diagnosis with the presence of lymph node involvement and metastases, survival drops drastically and is only 36%. A large proportion of oral cancer originates from potentially malignant oral mucosal lesions (PMOD) that occur in a prevalence of about 2-3% globally and over time are at risk of malignification. Of PMOD, oral leukoplakia (OL) is the most prevalent and most common in the group of middle-aged or older men. Swedish prevalence figures for OL have been reported to range from 0.7% to 3.5%. As patients with PMOD such as OL, erythroplakia (EP) or proliferative verrukös are at a significantly increased risk of developing oral cancer, it is important to include these patients in a functioning control system. This is especially true for risk individuals, those with an overconsumption of alcohol, with tobacco use, and those with chronic infection of tonsil and tongue base with high-risk human papillomavirus. About 80% of the adult population in Sweden is regularly examined at private dental care or public dental care, which means that general dental care can take a great responsibility for identifying and carrying out continuous checks on risk groups. A routine examination of the patient should include assessment of the oral mucosa according to clinical practice. Oral mucosal changes should be diagnosed and, if necessary, treatment initiated. In the case of a clinical diagnosis of OL, EP or verrukös leukoplakia, the clinical diagnosis should be verified with a tissue biopsy performed at a specialist clinic in orofacial medicine, oral surgery or ear-nose-throat clinic. Based on the diagnosis and degree of cell changes, it is decided according to current practice whether the continued treatment and the patient is included in a system for continuous checks. Oral cancer must be diagnosed early because mortality is high, especially in late diagnosis, and quality of life after treatment is very poor with significant pain, speech, chewing and swallowing difficulties with a strong impact on both family life and social contacts and working life. The solution is early detection and early treatment, which can be achieved if follow-up are performed in primary dental care with non-invasive brush biopsies for cytological diagnostics in a similar way to cervical cancer screening managed by midwives. Cytological diagnosis of oral mucosal changes is a safe, simple and rapid method with high sensitivity and specificity. With the present series of studies, the investigators intend to evaluate different possibilities to identify PMOD with high-grade dysplasias, and tumors early in order to improve prognosis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05296941
Study type Interventional
Source Dalarna County Council, Sweden
Contact Kristina Edman, PhD
Phone +46(0)70 5349476
Email kristina.edman@regiondalarna.se
Status Recruiting
Phase N/A
Start date August 1, 2023
Completion date December 31, 2029

See also
  Status Clinical Trial Phase
Terminated NCT01216020 - Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer Phase 2
Completed NCT00953849 - Vitamin D - Celecoxib Therapy Phase 1/Phase 2
Completed NCT01649349 - The Feasibility Study of Dual-Section Nasogastric Tube Phase 0
Completed NCT00721799 - F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients Phase 2
Recruiting NCT00193843 - Oral Cancer Adjuvant Therapy (OCAT) Trial Phase 3
Completed NCT04009811 - A New Membrane Obturator Prothesis Concept for Soft Palate Defects N/A
Terminated NCT00272181 - Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer Phase 2
Completed NCT01553851 - GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer Phase 2
Completed NCT02604121 - Cytological Screening for Early Diagnosis of Precancerous or Cancerous Lesions of Oral Cavity N/A
Recruiting NCT02290145 - Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage Phase 2
Terminated NCT00412776 - Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer Phase 2/Phase 3
Completed NCT06231537 - Visual Oral Examination for Early Detection of Oral Cancer in High-Risk Individuals N/A
Recruiting NCT02285530 - GDF15 Based TPF Induction Chemotherapy for OSCC Patients Phase 2
Terminated NCT02285543 - A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients Phase 2
Active, not recruiting NCT00341497 - Biomarkers for Oral Cancer
Completed NCT01195922 - Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Phase 1/Phase 2
Not yet recruiting NCT05774483 - Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative N/A
Completed NCT01104714 - Pharmacogenetic Response to Chemotherapy Induction for ORL Cancers N/A